Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Trimmed by Whittier Trust Co.

Whittier Trust Co. trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 87,421 shares of the medical research company’s stock after selling 358 shares during the quarter. Thermo Fisher Scientific makes up approximately 0.7% of Whittier Trust Co.’s holdings, making the stock its 28th largest position. Whittier Trust Co.’s holdings in Thermo Fisher Scientific were worth $54,075,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Brookstone Capital Management boosted its position in shares of Thermo Fisher Scientific by 252.4% in the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after purchasing an additional 3,142 shares during the period. BDF Gestion bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $6,368,000. Aviance Capital Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 20.9% during the 1st quarter. Aviance Capital Partners LLC now owns 13,043 shares of the medical research company’s stock worth $7,581,000 after buying an additional 2,251 shares during the period. Lord Abbett & CO. LLC raised its holdings in Thermo Fisher Scientific by 1.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock worth $45,478,000 after acquiring an additional 1,480 shares during the period. Finally, Advisors Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 5.8% during the first quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock valued at $64,613,000 after acquiring an additional 6,089 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on TMO shares. Raymond James raised their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. UBS Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $605.00 to $630.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Wells Fargo & Company initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, August 27th. They set an “overweight” rating and a $670.00 target price on the stock. Finally, Stephens assumed coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $656.16.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $7.76 during trading on Monday, reaching $593.95. The company’s stock had a trading volume of 466,565 shares, compared to its average volume of 1,461,975. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The stock has a market capitalization of $226.89 billion, a PE ratio of 37.33, a P/E/G ratio of 3.85 and a beta of 0.77. The firm has a fifty day moving average of $607.99 and a 200 day moving average of $584.23.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter in the previous year, the company earned $5.15 EPS. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. Analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 3,624 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the sale, the vice president now directly owns 13,699 shares in the company, valued at approximately $8,397,760.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 3,624 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the sale, the vice president now directly owns 13,699 shares in the company, valued at approximately $8,397,760.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $1,201,700.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,860,920.55. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 23,084 shares of company stock worth $14,094,292. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.